Akihiro Fujimoto

Akihiro Fujimoto

Auto-generated profile, based on publicly available information

Akihiro Fujimoto

Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2021 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
AFAkihiro Fujimoto
Akihiro Fujimoto
KMKazuo Matsuura
Kazuo Matsuura
THTakahiro Hasebe
Takahiro Hasebe
TSToshiaki Saeki
Toshiaki Saeki

13 September 2021 in Oxford Medical Case Reports
Verified
Journal Article
Open access
PDF file
AFAkihiro Fujimoto
Akihiro Fujimoto
KMKazuo Matsuura
Kazuo Matsuura
TKTomonori Kawasaki
Tomonori Kawasaki
YIYuki Ichinose
Yuki Ichinose
ANAsami Nukui
Asami Nukui
TSToshiaki Saeki
Toshiaki Saeki
Breast cancer arising from fibroadenoma (FA) is rare, in which almost all reported cases are human epidermal growth factor receptor 2 (HER2)-negative. This is the first report to describe a case of HER2-positive breast cancer arising from FA that was treated with chemotherapy plus anti-HER2 therapy. In this early case, upfront surgery outcomes guided the selection of appropriate systemic therapy. A 31-year-old woman previously diagnosed with FA experienced tumor growth. Core needle biopsy and imaging studies confirmed a diagnosis of stage IIA HER2-positive invasive ductal carcinoma (IDC) with no evidence of lymph node metastasis (cT2N0M0). Breast-conserving surgery was performed. Pathological diagnosis revealed stage IA IDC with a predominant intraductal component (pT1aN0M0), arising from FA. In conclusion, we encountered an extremely rare case of HER2-positive breast cancer arising from FA in which pathological infiltration was difficult to predict based on preoperative imaging.

23 June 2022 in Oxford Medical Case Reports
Verified
Journal Article
Open access
PDF file
AFAkihiro Fujimoto
Akihiro Fujimoto
ASAyaka Sakakibara
Ayaka Sakakibara
YNYoshiki Numajiri
Yoshiki Numajiri
KMKazuo Matsuura
Kazuo Matsuura
TKTomonori Kawasaki
Tomonori Kawasaki
TSToshiaki Saeki
Toshiaki Saeki
Carney complex (CNC) is a rare multiple tumour syndrome characterized by cutaneous pigmented lesions, myxoma and endocrine tumours, among others, and is inherited as an autosomal dominant trait. Protein kinase cAMP-dependent type I regulatory subunit alpha (PRKAR1A) is known to be the responsible gene. Breast myxomatosis and ductal adenoma, which are regarded as benign, are well-known mammary lesions of CNC and are included in the main diagnostic criteria. In this case, a 59-year-old woman with repeated cardiac myxoma was diagnosed with CNC with PRKAR1A mutation. She also had three multiple breast tumours bilaterally: breast cancer, adenomyoepithelioma and intraductal papilloma. In mammary lesions of CNC, attention should be paid to benign lesions, such as breast myxomatosis or ductal adenomas, and the development of breast cancer or breast tumours with malignant potential. Mammary lesions should be aggressively scrutinized and considered for resection, as required.

21 September 2021 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
AFAkihiro Fujimoto
Akihiro Fujimoto
YKYoshimasa Kosaka
Yoshimasa Kosaka
THTakahiro Hasebe
Takahiro Hasebe
TSToshiaki Saeki
Toshiaki Saeki
The main concern after breast augmentation with silicone injection is that silicone granulomas make it difficult to detect breast cancer. A case of breast cancer was diagnosed using colour Doppler ultrasound (CD) to detect an non-palpable mass not presenting as a hypoechoic mass lesion. An 83-year-old woman was incidentally found to have a lesion in her right breast, which was injected with silicone, showing 18F-fluorodeoxyglucose (FDG) uptake; the lesion was suspected to be breast cancer or silicone granuloma. A mass at the FDG uptake site was not detected on ultrasonography (US); however, observation using CD revealed a slightly hypoechoic area with hypervascularity. Core needle biopsy showed invasive ductal carcinoma. Patients in whom US does not reveal lesions after breast augmentation with silicone injection should undergo CD to detect hypervascularised tissue. To prevent false-negative biopsy results, CD is essential to detect cancer at suspected sites.

1 July 2026 in Cancer Diagnosis & Prognosis
Verified
Journal Article
Open access
AFAkihiro Fujimoto
Akihiro Fujimoto
YIYuki Ichinose
Yuki Ichinose
KMKazuo Matsuura
Kazuo Matsuura
EMEmi Mikami
Emi Mikami
WIWakako Inohana
Wakako Inohana
TSToshiaki Saeki
Toshiaki Saeki
Background/Aim: Immune checkpoint inhibitors (ICIs) have improved clinical outcomes in patients with advanced triple-negative breast cancer (TNBC); however, substantial heterogeneity exists in treatment durability and survival. Simple blood-based immune markers may provide prognostic information; however, their clinical relevance in ICI-treated TNBC remain unclear. Patients and Methods: We conducted a retrospective single-center study of patients with advanced TNBC treated with ICIs, including atezolizumab or pembrolizumab. Baseline peripheral immune markers – absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) – were evaluated prior to treatment initiation. Time-to-treatment failure (TTF) and overall survival (OS) were analyzed using the Kaplan–Meier method and Cox proportional hazards model. Results: A total of 43 patients were included. In the Kaplan–Meier analysis, high baseline NLR was significantly associated with both shorter TTF and OS. Low baseline ALC was significantly associated with shorter TTF but not with OS. In the multivariate Cox proportional hazards analysis of TTF, no baseline clinical or immune parameters were identified as independent prognostic factors. In contrast, multivariate analysis for OS demonstrated that high baseline NLR was the only independent prognostic factor. Conclusion: NLR was independently associated with OS, suggesting it functions as a prognostic marker of systemic inflammatory and immune balance. In contrast, ALC was associated with treatment durability but not long-term survival, indicating its relevance to treatment tolerance rather than survival outcomes. These findings highlight the clinical utility of simple blood-based immune markers for risk stratification in ICI-treated TNBC.

22 June 2021 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
AFAkihiro Fujimoto
Akihiro Fujimoto
HYHirofumi Yamada
Hirofumi Yamada
THTakahiro Hasebe
Takahiro Hasebe
TSToshiaki Saeki
Toshiaki Saeki